综述 |
|
|
|
|
麻疹病毒抗肿瘤作用的研究进展 |
周朵, 赵正言 |
浙江大学医学院附属儿童医院儿保科, 浙江 杭州 310003 |
|
Advances in measles virus for cancer therapy |
ZHOU Duo, ZHAO Zheng-yan |
Pediatric Health Care Department, the Children's Hospital Zhejiang University School of Medicine, Hangzhou 310003, China |
[1] |
MSAOUEL P, OPYRCHAL M, DOMINGO MUSIBAY E, et al. Oncolytic measles virus strains as novel anticancer agents[J]. Expert Opin Biol Ther, 2013,13(4):483-502.
|
[2] |
RUSSELL S J, PENG K W, BELL J C. Oncolytic virotherapy[J]. Nat Biotechnol, 2012,30(7):658-670.
|
[3] |
FIELDING A K. Measles as a potential oncolytic virus[J]. Rev Med Virol, 2005, 15(2):135-142.
|
[4] |
GRIFFIN D E, PAN C H.Measles: old vaccines, new vaccines[J]. Curr Top Microbiol Immunol, 2009,330: 191-212.
|
[5] |
LECH P J, RUSSELL S J. Use of attenuated paramyxoviruses for cancer therapy[J]. Expert Rev Vaccines, 2010,9(11):1275-1302.
|
[6] |
NAVARATNARAJAH C K, OEZGUEN N,RUPP L, et al. The heads of the measles virus attachment protein move to transmit the fusion-triggering signal[J]. Nat Struct Mol Biol, 2011,18(2):128-134.
|
[7] |
WILD T F, MALVOISIN E, BUCKLAND R.Measles virus both the haemagglutinin and fusion glycoproteins are required for fusion [J]. J Gen virol, 1991,72(pt 2):439-442.
|
[8] |
Centers for Disease Control and Prevention. Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection,1993[J]. MMWR Morb Mortal Wkly Rep, 1996,45(28):603-606.
|
[9] |
BLUMING A Z, ZIEGLER J L. Regression of Burkitt's lymphoma in association with measles infection[J]. Lancet, 1971,2(7715):105-106.
|
[10] |
PASQUINUCCI G. Possible effect of measles on leukaemia[J]. Lancet, 1971,1(7690): 136.
|
[11] |
ZYGIERT Z. Hodgkin's disease: remissions after measles[J]. Lancet, 1971,1(7699): 593.
|
[12] |
MSAOUEL P, DISPENZIERI A, GALANIS E.Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview[J]. Curr Opin Mol Ther, 2009,11(1):43-53.
|
[13] |
NAKAMURA T, PENG K W, HARVEY M,et al.Rescue and propagation of fully retargeted oncolytic measles viruses[J]. Nat Biotechnol, 2005,23(2):209-214.
|
[14] |
YAIW K C, MIEST T S, FRENZKE M, et al. CD20-targeted measles virus shows high oncolytic specificity in clinical samples from lymphoma patients independent of prior rituximab therapy[J]. Gene Ther, 2011,18(3):313-317.
|
[15] |
M Parrula M C, FERNANDEZ S A, LANDES K, et al. Success of measles virotherapy in ATL depends on type I interferon secretion and responsiveness[J]. Virus Res, 2014,189:206-213.
|
[16] |
THIRUKKUMARAN C M, MORRIS D G. Oncolytic virotherapy for multiple myeloma: past, present,and future[J]. Bone Marrow Res, 2011,2011:632-948.
|
[17] |
ZEMP F J, CORREDOR J C, LUN X Q, et al. Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil[J]. Cytokine & Growth Factor Rev, 2010,21(2-3):103-117.
|
[18] |
LI H, PENG K W, DINGLI D, et al. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy[J]. Cancer Gene Ther, 2010,17(8):550-558.
|
[19] |
DONNELLY O G, ERRINGTON-MAIS F, STEELE L, et al. Measles virus causes immunogenic cell death in human melanoma[J]. Gene Ther, 2013,20(1):7-15.
|
[20] |
HARTKOPF A D, BOSSOW S, LAMPE J, et al. Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase[J]. Gynecol Oncol, 2013,130(2):362-368.
|
[21] |
IANKOV I D, MSAOUEL P, ALLEN C, et al. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model [J]. Breast Cancer Res Treat, 2010,122(3):745-754.
|
[22] |
LIU Y P, STEELE M B, SUKSANPAISAN L, et al. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer[J]. Gynecol Oncol, 2014,132(1): 194-202.
|
[23] |
SUGIYAMA T, YONEDA M, KURAISHI T, et al. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment[J]. Gene Ther,2013,20(3):338-347.
|
[24] |
LIU C S, HASEGAWA K, RUSSELL S J, et al. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer[J]. Prostate, 2009,69(10):1128-1141.
|
[25] |
BOSSOW S, GROSSARDT C, TEMME A, et al. Armed and targeted measles virus for chemovirotherapy of pancreatic cancer[J]. Cancer Gene Ther, 2011,18(8):598-608.
|
[26] |
XIA M,MENG G, JIANG A, et al. Mitophagy switches cell death from apoptosis to necrosis in NSCLC cells treated with oncolytic measles virus[J]. Oncotarget, 2014,5(11):3907-3918.
|
[27] |
BOISGERAULT N, GUILLERME J B, POULIQUEN D, et al. Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas[J]. Biomed Res Int, 2013,2013: 387362.
|
[28] |
ONG H T, FEDERSPIEL M J, GUO C M, et al. Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth[J]. J Hepatol, 2013,59(5):999-1006.
|
[29] |
HSU E C, IORIO C, SARANGI F, et al. CDw150(SLAM) is a receptor for a lymphotropic strain of measles virus and may account for the immunosuppressive properties of this virus[J]. Virology, 2001,279(1):151.
|
[30] |
MANCHESTER M, NANICHE D, STEHLE T.CD46 as a measles receptor: form follows function[J]. Virology, 2000,274(1):5-10.
|
[31] |
MUHLEBACH M D, MATEO M, SINN P L, et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus[J]. Nature, 2011,480(7378):530-533.
|
[32] |
PENG K W, TENEYCK C J, GALANIS E, et al. Intraperitoneal therapy of ovarian cancer using an engineered measles virus[J]. Cancer Res, 2002,62(12):4656-4662.
|
[33] |
DELPEUT S, NOYCE R S,RICHARDSON C D.The tumor-associated marker,PVRL4 (nectin-4), is the epithelial receptor for morbilliviruses[J]. Viruses, 2014,6(6):2268-2286.
|
[34] |
MASSE N, AINOUZE M, NEEL B, et al. Measles virus (MV) hemagglutinin: evidence that attachment sites for MV receptors SLAM and CD46 overlap on the globular head[J]. J Virol, 2004,78(17):9051-9063.
|
[35] |
NOYCE R S, BONDRE D G, HA M N, et al. Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus[J]. PLoS Pathog, 2011,7(8):e1002240.
|
[36] |
ZHANG X, LU G, QI J, et al. Structure of measles virus hemagglutinin bound to its epithelial receptor nectin-4[J]. Nat Struct Mol Biol, 2013,20(1):67-72.
|
[37] |
YANAGI Y, TAKEDA M, OHNO S.Measles virus: cellular receptors,tropism and pathogenesis[J]. J Gen Virol, 2006,87(pt 10):2767-2779.
|
[38] |
PENG K W, FACTEAU S, WEGMAN T,et al.Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides[J]. Nat Med, 2002,8(5): 527-531.
|
[39] |
GALANIS E, HARTMANN L C, CLIBY W A, et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer[J]. Cancer Res, 2010,70(3): 875-882.
|
[40] |
DINGLI D, PENG K W, HARVEY M E, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter[J].Blood, 2004,103(5):1641-1646.
|
[41] |
DADACHOVA E, CARRASCO N.The Na/I symporter(NIS): imaging and therapeutic applications[J]. Semin Nucl Med, 2004,34(1):23-31.
|
[42] |
CARLSON S K, CLASSIC K L, HADAC E M, et al. In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography/computed tomography[J]. Mol Imaging Biol, 2006,8(6):324-332.
|
[43] |
RUSSELL S J, FEDERSPIEL M J, PENG K W, et al. Remission of disseminated cancer after systemic oncolytic virotherapy[J]. Mayo Clin Proc, 2014,89(7):926-933.
|
[44] |
HUTZEN B, PIERSON C R, RUSSELL S J,et al.Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine[J]. BMC Cancer, 2012,12: 508.
|
[45] |
LIU Y P, STEELE M B, SUKSANPAISAN L, et al. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer[J]. Gynecol Oncol, 2014,132(1):194-202.
|
[46] |
OPYRCHAL M, ALLEN C, IANKOV I, et al. Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter(MV-NIS)[J].Hum Gene Ther, 2012,23(4):419-427.
|
[47] |
GOTOH B, KOMATSU T, TAKEUCHI K, et al. Paramyxovirus accessory proteins as interferon antagonists[J]. Microbiol Immunol, 2001,45(12):787-800.
|
[48] |
HARALAMBIEVA I, IANKOV I, HASEGAWA K, et al. Engineering oncolytic measles virus to circumvent the intracellular innate immune response[J]. Mol Ther, 2007,15(3): 588-597.
|
[49] |
SCHNEIDER U, BULLOUGH F, VONGPUNSAWAD S, et al. Recombinant measles viruses efficiently entering cells through targeted receptors[J]. J Virol, 2000,74(21):9928-9936.
|
[50] |
PENG K W, DONOVAN K A, SCHNEIDER U, et al. Oncolytic measles viruses displaying a single-chain antibody against CD38,a myeloma cell marker[J]. Blood, 2003,101(7):2557-2562.
|
[51] |
KNEISSL S, ZHOU Q, SCHWENKERT M, et al. CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes[J]. PLoS One, 2013,8(11):e79047.
|
[52] |
PENG K W, HOLLER P D, ORR B A, et al. Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor[J]. Gene Ther, 2004,11(15):1234-1239.
|
[53] |
HEINZERLING L, KUNZI V, OBERHOLZER P A, et al. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells[J]. Blood, 2005,106(7):2287-2294.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|